Genome editing technologies hold great promise for numerous applications including the
understanding of cellular and disease mechanisms and the development of gene and …

Engineered live bacteria could provide a new modality for treating lung infections, a major
cause of mortality worldwide. In the present study, we engineered a genome-reduced …

Mesoplasma florum is an emerging model organism for systems and synthetic biology due
to its small genome (∼ 800 kb) and fast growth rate. While M. florum was isolated and first …

Microbiology and synthetic biology depend on reverse genetic approaches to manipulate
bacterial genomes; however, existing methods require molecular biology to generate …

A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of
live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting …

Large gene libraries are frequently created in Escherichia coli plasmids, which can induce
cell toxicity and expression instability due to the high gene dosage. To address these …

Mycoplasma belong to the genus Mollicutes and are notable for their small genome sizes
(500–1300 kb) and limited biosynthetic capabilities. They exhibit pathogenicity by invading …

Mycoplasma capricolum subspecies capripneumoniae (Mccp) is the causative agent of
contagious caprine pleuropneumonia (CCPP), a devastating disease listed by the World …

At Pulmobiotics, we engineer bacteria for the treatment of respiratory diseases. Here, we
outline how we designed MycoChassis—an attenuated bacterium strain obtained by …